Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,367
archived clinical trials in
High Blood Pressure (Hypertension)

Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease
Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease
Status: Enrolling
Updated:  12/31/1969
New York University School of Medicine
mi
from
New York, NY
Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease
Using Practice Facilitation in Primary Care Settings to Reduce Risk Factors for Cardiovascular Disease
Status: Enrolling
Updated: 12/31/1969
New York University School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
A Nutritional Intervention in Police Officers
A Nutritional Intervention in Police Officers
Status: Enrolling
Updated:  12/31/1969
Physicians Committee for Responsible Medicine
mi
from
Washington,
A Nutritional Intervention in Police Officers
A Nutritional Intervention in Police Officers
Status: Enrolling
Updated: 12/31/1969
Physicians Committee for Responsible Medicine
mi
from
Washington,
Click here to add this to my saved trials
New International CTEPH Database
New International CTEPH Database
Status: Enrolling
Updated:  12/31/1969
UC San Diego
mi
from
La Jolla, CA
New International CTEPH Database
New International CTEPH Database
Status: Enrolling
Updated: 12/31/1969
UC San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
New International CTEPH Database
New International CTEPH Database
Status: Enrolling
Updated:  12/31/1969
University of Maryland
mi
from
Baltimore, MD
New International CTEPH Database
New International CTEPH Database
Status: Enrolling
Updated: 12/31/1969
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
New International CTEPH Database
New International CTEPH Database
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
New International CTEPH Database
New International CTEPH Database
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic
mi
from
Cleveland, OH
Click here to add this to my saved trials
New International CTEPH Database
New International CTEPH Database
Status: Enrolling
Updated:  12/31/1969
St Vincent's Hospital
mi
from
Darlinghurst,
New International CTEPH Database
New International CTEPH Database
Status: Enrolling
Updated: 12/31/1969
St Vincent's Hospital
mi
from
Darlinghurst,
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Appalachian Cardiovascular Associates
mi
from
Fort Payne, AL
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Appalachian Cardiovascular Associates
mi
from
Fort Payne, AL
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Long Beach CTR for Clin Research
mi
from
Long Beach, CA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Long Beach CTR for Clin Research
mi
from
Long Beach, CA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Orange County Research Center
mi
from
Tustin, CA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Orange County Research Center
mi
from
Tustin, CA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Consulting, LLC
mi
from
Milford, CT
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Consulting, LLC
mi
from
Milford, CT
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Chase Medical Research, LLC
mi
from
Waterbury, CT
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Chase Medical Research, LLC
mi
from
Waterbury, CT
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Innovative Research of West Florida, Inc.
mi
from
Clearwater, FL
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Innovative Research of West Florida, Inc.
mi
from
Clearwater, FL
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Canvas Clinical Research
mi
from
Lake Worth, FL
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Canvas Clinical Research
mi
from
Lake Worth, FL
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
LCC Medical Research Institute, LLC
mi
from
Miami, FL
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
LCC Medical Research Institute, LLC
mi
from
Miami, FL
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Allied Biomedical Research Institute
mi
from
Miami, FL
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Allied Biomedical Research Institute
mi
from
Miami, FL
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Avant Research Associates, LLC
mi
from
Crowley, LA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Avant Research Associates, LLC
mi
from
Crowley, LA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
New Orleans Center for Clinical Research - Nola
mi
from
New Orleans, LA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
New Orleans Center for Clinical Research - Nola
mi
from
New Orleans, LA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Diagnostic Center of Medicine - Spring Valley/Radiant Rese
mi
from
Las Vegas, NV
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Diagnostic Center of Medicine - Spring Valley/Radiant Rese
mi
from
Las Vegas, NV
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Peters Medical Research
mi
from
HIgh Point, NC
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Peters Medical Research
mi
from
HIgh Point, NC
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Lillestol Research LLC
mi
from
Fargo, ND
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Lillestol Research LLC
mi
from
Fargo, ND
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Sterling Research Group
mi
from
Cincinnati, OH
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Sterling Research Group
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Aventiv Research
mi
from
Columbus, OH
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Aventiv Research
mi
from
Columbus, OH
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Aventiv Research Inc.
mi
from
Dublin, OH
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Aventiv Research Inc.
mi
from
Dublin, OH
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
DeGarmo Institute of Medical Research
mi
from
Greer, SC
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
DeGarmo Institute of Medical Research
mi
from
Greer, SC
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Volunteer Research Group
mi
from
Knoxville, TN
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Volunteer Research Group
mi
from
Knoxville, TN
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Texas Diabetes & Endocrinology, PA
mi
from
Austin, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Texas Diabetes & Endocrinology, PA
mi
from
Austin, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Trinity Hypertension & Metabolic Research Institute
mi
from
Carrollton, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Trinity Hypertension & Metabolic Research Institute
mi
from
Carrollton, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Coastal Blend Clinical Reserch
mi
from
Corpus Christi, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Coastal Blend Clinical Reserch
mi
from
Corpus Christi, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Global Medical Research
mi
from
DeSoto, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Global Medical Research
mi
from
DeSoto, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Ventavia Research Group, LLC
mi
from
Fort Worth, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Ventavia Research Group, LLC
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Clinical Investigations of Texas
mi
from
Plano, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Clinical Investigations of Texas
mi
from
Plano, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Texas Diabetes and Endocrinology
mi
from
Round Rock, TX
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Texas Diabetes and Endocrinology
mi
from
Round Rock, TX
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Health Research of Hampton Roads
mi
from
Newport News, VA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Health Research of Hampton Roads
mi
from
Newport News, VA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Radiant Research
mi
from
Chandler, AZ
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Radiant Research
mi
from
Chandler, AZ
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Warner Family Practice / Radiant Research Inc
mi
from
Chandler, AZ
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Warner Family Practice / Radiant Research Inc
mi
from
Chandler, AZ
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Phoenix Medical Research Institute, LLC
mi
from
Peoria, AZ
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Phoenix Medical Research Institute, LLC
mi
from
Peoria, AZ
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Desert Sun Clinical Research, LLC
mi
from
Tucson, AZ
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Desert Sun Clinical Research, LLC
mi
from
Tucson, AZ
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Advanced Research Center, Inc.
mi
from
Anaheim, CA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Advanced Research Center, Inc.
mi
from
Anaheim, CA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Med Center
mi
from
Carmichael, CA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Med Center
mi
from
Carmichael, CA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
John Muir Physician Network Clinical Research Center
mi
from
Concord, CA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
John Muir Physician Network Clinical Research Center
mi
from
Concord, CA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Clinical Trials Research
mi
from
Lincoln, CA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Clinical Trials Research
mi
from
Lincoln, CA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Entertainment Medical Group Inc
mi
from
Los Angeles, CA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Entertainment Medical Group Inc
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Empire Clinical Research
mi
from
Upland, CA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Empire Clinical Research
mi
from
Upland, CA
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Alfieri Cardiology
mi
from
Wilmington, DE
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Alfieri Cardiology
mi
from
Wilmington, DE
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
ACRC - Cardiology
mi
from
Atlantis, FL
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
ACRC - Cardiology
mi
from
Atlantis, FL
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
AGA Clinical Trials
mi
from
Hialeah, FL
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
AGA Clinical Trials
mi
from
Hialeah, FL
Click here to add this to my saved trials
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated:  12/31/1969
Southeast Regional Research Group
mi
from
Savannah, GA
Clinical Study to Explore the Effects of Actelion's Latest Endothelin Receptor Antagonist (ERA) - at Different Dose Strengths - on the Efficacy, Safety and Tolerability in Subjects With Essential Hypertension
Multi-center, Double-blind, Double-dummy, Randomized, Placebo- and Active-reference, Parallel Group, Phase 2 Dose-finding Study With Actelion's Latest Endothelin Receptor Antagonist (ERA) in Subjects With Essential Hypertension (Grade 1 and 2)
Status: Enrolling
Updated: 12/31/1969
Southeast Regional Research Group
mi
from
Savannah, GA
Click here to add this to my saved trials